SCHEMBL378806

SCHEMBL378806

CCOC(=O)C1(CC2CCC2)CCN(C(=O)c2ccc(-c3ccc(F)cc3)cc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 5/20 0.54
MEN1 O00255 6/20 0.48
KMT2A Q03164 6/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
MAPK1 P28482 1/20 0.48
HTT P42858 1/20 0.47
GAA P10253 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
ALDH1A1 P00352 2/20 0.44
RECQL P46063 1/20 0.44
OPRM1 P35372 2/20 0.44
OPRD1 P41143 1/20 0.44
HSD11B1 P28845 1/20 0.43
MAPT P10636 1/20 0.43
PKM P14618 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
P4HB P07237 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL378387 0.96 POLB (0.58) POLBMEN1KMT2AL3MBTL1MAPK1
SCHEMBL378643 0.85 HSD11B1 (0.51) MEN1KMT2AL3MBTL1MAPK1ALDH1A1
SCHEMBL378819 0.82 PKLR (0.53) POLBMEN1KMT2AL3MBTL1HTT
SCHEMBL378419 0.82 MEN1 (0.45) POLBMEN1KMT2AL3MBTL1HTT
SCHEMBL379371 0.81 OPRM1 (0.67) MEN1KMT2AHTTOPRM1OPRD1
SCHEMBL3098857 0.80 MEN1 (0.48) POLBMEN1KMT2AHTTALDH1A1
SCHEMBL378365 0.80 HSD11B1 (0.53) MEN1KMT2AL3MBTL1ALDH1A1HSD11B1
SCHEMBL13092319 0.79 MAPT (0.46) POLBKMT2AALDH1A1OPRD1HSD11B1
SCHEMBL2433795 0.78 PTGER2 (0.56) POLBMEN1KMT2AL3MBTL1HTT
SCHEMBL2434943 0.76 KMT2A (0.46) POLBMEN1KMT2AL3MBTL1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
EP-2408745-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2012-01-25 EP disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 POLB 2329/4885MEN1 4869/4885KMT2A 1488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.